BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12409224)

  • 1. In vitro and in vivo treatment of colon cancer by VIP antagonists.
    Levy A; Gal R; Granoth R; Dreznik Z; Fridkin M; Gozes I
    Regul Pept; 2002 Nov; 109(1-3):127-33. PubMed ID: 12409224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells.
    Moody TW; Leyton J; Chan D; Brenneman DC; Fridkin M; Gelber E; Levy A; Gozes I
    Breast Cancer Res Treat; 2001 Jul; 68(1):55-64. PubMed ID: 11678309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A vasoactive intestinal peptide antagonist inhibits non-small cell lung cancer growth.
    Moody TW; Zia F; Draoui M; Brenneman DE; Fridkin M; Davidson A; Gozes I
    Proc Natl Acad Sci U S A; 1993 May; 90(10):4345-9. PubMed ID: 8389448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A lipophilic vasoactive intestinal peptide analog enhances the antiproliferative effect of chemotherapeutic agents on cancer cell lines.
    Gelber E; Granoth R; Fridkin M; Dreznik Z; Brenneman DE; Moody TW; Gozes I
    Cancer; 2001 Oct; 92(8):2172-80. PubMed ID: 11596035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of PC-3 human prostate cancers by analogs of growth hormone-releasing hormone (GH-RH) endowed with vasoactive intestinal peptide (VIP) antagonistic activity.
    Plonowski A; Varga JL; Schally AV; Krupa M; Groot K; Halmos G
    Int J Cancer; 2002 Apr; 98(4):624-9. PubMed ID: 11920625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (N-stearyl, norleucine17) VIP hybrid inhibits the growth of pancreatic cancer cell lines.
    Zia H; Leyton J; Casibang M; Hau V; Brenneman D; Fridkin M; Gozes I; Moody TW
    Life Sci; 2000; 66(5):379-87. PubMed ID: 10670826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro.
    Dufes C; Alleaume C; Montoni A; Olivier JC; Muller JM
    J Mol Neurosci; 2003; 21(2):91-102. PubMed ID: 14593209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human neuroblastoma growth by a specific VIP antagonist.
    Lilling G; Wollman Y; Goldstein MN; Rubinraut S; Fridkin M; Brenneman DE; Gozes I
    J Mol Neurosci; 1994-1995; 5(4):231-9. PubMed ID: 7577366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
    J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
    Akesson L; Ahrén B; Edgren G; Degerman E
    Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation.
    Vacas E; Fernández-Martínez AB; Bajo AM; Sánchez-Chapado M; Schally AV; Prieto JC; Carmena MJ
    Biochim Biophys Acta; 2012 Oct; 1823(10):1676-85. PubMed ID: 22728770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1.
    Balster DA; O'Dorisio MS; Albers AR; Park SK; Qualman SJ
    Regul Pept; 2002 Nov; 109(1-3):155-65. PubMed ID: 12409228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist.
    Zia H; Hida T; Jakowlew S; Birrer M; Gozes Y; Reubi JC; Fridkin M; Gozes I; Moody TW
    Cancer Res; 1996 Aug; 56(15):3486-9. PubMed ID: 8758916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimulation of tumor cell growth by vasoactive intestinal peptide.
    Scholar EM; Paul S
    Cancer; 1991 Mar; 67(6):1561-4. PubMed ID: 2001545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoic acid regulation of the VIP and PACAP autocrine ligand and receptor system in human neuroblastoma cell lines.
    Waschek JA; Lelievre V; Bravo DT; Nguyen T; Muller JM
    Peptides; 1997; 18(6):835-41. PubMed ID: 9285932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasoactive intestinal peptide (VIP) stimulates in vitro growth of VIP-1 receptor-bearing human pancreatic adenocarcinoma-derived cells.
    Jiang S; Kopras E; McMichael M; Bell RH; Ulrich CD
    Cancer Res; 1997 Apr; 57(8):1475-80. PubMed ID: 9108448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of vasoactive intestinal peptide and functional VIP receptors in human prostate cancer: antagonistic action of a growth-hormone-releasing hormone analog.
    Collado B; Carmena MJ; Sánchez-Chapado M; Ruíz-Villaespesa A; Bajo AM; Fernández-Martínez AB; Varga JL; Schally AV; Prieto JC
    Int J Oncol; 2005 Jun; 26(6):1629-35. PubMed ID: 15870879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
    Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis.
    Zupan V; Hill JM; Brenneman DE; Gozes I; Fridkin M; Robberecht P; Evrard P; Gressens P
    J Neurochem; 1998 May; 70(5):2165-73. PubMed ID: 9572304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An antagonist to vasoactive intestinal peptide affects cellular functions in the central nervous system.
    Gozes I; McCune SK; Jacobson L; Warren D; Moody TW; Fridkin M; Brenneman DE
    J Pharmacol Exp Ther; 1991 Jun; 257(3):959-66. PubMed ID: 1646331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.